136 related articles for article (PubMed ID: 27349866)
1. Echinocystic acid inhibits RANKL-induced osteoclastogenesis by regulating NF-κB and ERK signaling pathways.
Yang JH; Li B; Wu Q; Lv JG; Nie HY
Biochem Biophys Res Commun; 2016 Sep; 477(4):673-677. PubMed ID: 27349866
[TBL] [Abstract][Full Text] [Related]
2. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
[TBL] [Abstract][Full Text] [Related]
3. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
4. Saikosaponin a inhibits RANKL-induced osteoclastogenesis by suppressing NF-κB and MAPK pathways.
Zhou C; Liu W; He W; Wang H; Chen Q; Song H
Int Immunopharmacol; 2015 Mar; 25(1):49-54. PubMed ID: 25617149
[TBL] [Abstract][Full Text] [Related]
5. Gentiopicroside inhibits RANKL-induced osteoclastogenesis by regulating NF-κB and JNK signaling pathways.
Chen F; Xie L; Kang R; Deng R; Xi Z; Sun D; Zhu J; Wang L
Biomed Pharmacother; 2018 Apr; 100():142-146. PubMed ID: 29428661
[TBL] [Abstract][Full Text] [Related]
6. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation.
Wang C; Steer JH; Joyce DA; Yip KH; Zheng MH; Xu J
J Bone Miner Res; 2003 Dec; 18(12):2159-68. PubMed ID: 14672351
[TBL] [Abstract][Full Text] [Related]
7. Leonurine hydrochloride inhibits osteoclastogenesis and prevents osteoporosis associated with estrogen deficiency by inhibiting the NF-κB and PI3K/Akt signaling pathways.
Yuan FL; Xu RS; Jiang DL; He XL; Su Q; Jin C; Li X
Bone; 2015 Jun; 75():128-37. PubMed ID: 25708053
[TBL] [Abstract][Full Text] [Related]
8. Sophorae Flos extract inhibits RANKL-induced osteoclast differentiation by suppressing the NF-κB/NFATc1 pathway in mouse bone marrow cells.
Kim JM; Lee JH; Lee GS; Noh EM; Song HK; Gu DR; Kim SC; Lee SH; Kwon KB; Lee YR
BMC Complement Altern Med; 2017 Mar; 17(1):164. PubMed ID: 28335757
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-4 reversibly inhibits osteoclastogenesis via inhibition of NF-kappa B and mitogen-activated protein kinase signaling.
Wei S; Wang MW; Teitelbaum SL; Ross FP
J Biol Chem; 2002 Feb; 277(8):6622-30. PubMed ID: 11719504
[TBL] [Abstract][Full Text] [Related]
10. Icariin inhibits RANKL-induced osteoclastogenesis via modulation of the NF-κB and MAPK signaling pathways.
Xu Q; Chen G; Liu X; Dai M; Zhang B
Biochem Biophys Res Commun; 2019 Jan; 508(3):902-906. PubMed ID: 30538045
[TBL] [Abstract][Full Text] [Related]
11. Gypenoside inhibits RANKL-induced osteoclastogenesis by regulating NF-κB, AKT, and MAPK signaling pathways.
Han J; Gao W; Su D; Liu Y
J Cell Biochem; 2018 Sep; 119(9):7310-7318. PubMed ID: 29797602
[TBL] [Abstract][Full Text] [Related]
12. Bajijiasu Abrogates Osteoclast Differentiation via the Suppression of RANKL Signaling Pathways through NF-κB and NFAT.
Hong G; Zhou L; Shi X; He W; Wang H; Wei Q; Chen P; Qi L; Tickner J; Lin L; Xu J
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28106828
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
[TBL] [Abstract][Full Text] [Related]
14. Amyloid β Peptide Enhances RANKL-Induced Osteoclast Activation through NF-κB, ERK, and Calcium Oscillation Signaling.
Li S; Yang B; Teguh D; Zhou L; Xu J; Rong L
Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27735865
[TBL] [Abstract][Full Text] [Related]
15. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.
Lee JH; Jin H; Shim HE; Kim HN; Ha H; Lee ZH
Mol Pharmacol; 2010 Jan; 77(1):17-25. PubMed ID: 19828731
[TBL] [Abstract][Full Text] [Related]
16. Ginsenoside Rh2 inhibits osteoclastogenesis through down-regulation of NF-κB, NFATc1 and c-Fos.
He L; Lee J; Jang JH; Lee SH; Nan MH; Oh BC; Lee SG; Kim HH; Soung NK; Ahn JS; Kim BY
Bone; 2012 Jun; 50(6):1207-13. PubMed ID: 22484180
[TBL] [Abstract][Full Text] [Related]
17. Jolkinolide B inhibits RANKL-induced osteoclastogenesis by suppressing the activation NF-κB and MAPK signaling pathways.
Ma X; Liu Y; Zhang Y; Yu X; Wang W; Zhao D
Biochem Biophys Res Commun; 2014 Mar; 445(2):282-8. PubMed ID: 24491533
[TBL] [Abstract][Full Text] [Related]
18. Agelasine D suppresses RANKL-induced osteoclastogenesis via down-regulation of c-Fos, NFATc1 and NF-κB.
Kang MR; Jo SA; Yoon YD; Park KH; Oh SJ; Yun J; Lee CW; Nam KH; Kim Y; Han SB; Yu J; Rho J; Kang JS
Mar Drugs; 2014 Nov; 12(11):5643-56. PubMed ID: 25421321
[TBL] [Abstract][Full Text] [Related]
19. Suppression of osteoclastogenesis by N,N-dimethyl-D-erythro-sphingosine: a sphingosine kinase inhibition-independent action.
Kim HJ; Lee Y; Chang EJ; Kim HM; Hong SP; Lee ZH; Ryu J; Kim HH
Mol Pharmacol; 2007 Aug; 72(2):418-28. PubMed ID: 17504945
[TBL] [Abstract][Full Text] [Related]
20. Paeonol inhibits RANKL-induced osteoclastogenesis by inhibiting ERK, p38 and NF-kappaB pathway.
Tsai HY; Lin HY; Fong YC; Wu JB; Chen YF; Tsuzuki M; Tang CH
Eur J Pharmacol; 2008 Jun; 588(1):124-33. PubMed ID: 18495114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]